Trial
NCT02797522
A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Arrowhead Pharmaceuticals
Collaborators
—
Condition
Hepatitis B
Intervention
ARC-521 Injection
Why stopped
Company decision to discontinue trial
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-12